e.g. mhealth
Search Results (1 to 4 of 4 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Mental Health
- 1 JMIR Dermatology
- 1 JMIR Research Protocols
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
The Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), patient advocacy groups, and others have taken significant steps to curb inappropriate antipsychotic use in vulnerable older adults [3-5]. In 2012, the CMS debuted the National Partnership to Improve Dementia Care in Nursing Homes, an initiative that included targeted efforts to reduce antipsychotic use among nursing home residents with Alzheimer disease (AD) or AD-related dementias (ADRD) [1].
JMIR Res Protoc 2024;13:e64446
Download Citation: END BibTex RIS
Specific approval of the ingestible sensor system with the atypical antipsychotic aripiprazole was obtained in 2017 [10,11]. Aripiprazole, originally approved for use in schizophrenia [12], is also currently approved for use as an adjunct or monotherapy in bipolar I mania [13-17] and major depressive disorder [18]. Approval of digital aripiprazole included the use of an app tailored specifically for patients with serious mental illness under the name Abilify Mycite System [19].
JMIR Ment Health 2022;9(12):e39047
Download Citation: END BibTex RIS
A very recent study explored the use of financial incentives to increase oral antidepressant adherence [26], and 2 studies have focused on antipsychotic medication [27,28], both limited to long-acting injectables. To our knowledge, no study to date has examined the effects of financial incentives on adherence to neuropsychiatric treatments including oral antipsychotic medication.
JMIR Ment Health 2022;9(10):e37184
Download Citation: END BibTex RIS
Treatments for Primary Delusional Infestation: Systematic Review
A more recent systematic review reported similar results; there was no strong evidence to suggest any single antipsychotic agent over another [12]. Both of these reviews restricted their search strategy to antipsychotics; however, other pharmacological agents may also prove effective in treating delusional infestation.
JMIR Dermatol 2022;5(1):e34323
Download Citation: END BibTex RIS